Equillium announces second quarter 2024 estimated cash and investments balance

La jolla, calif.--(business wire)---- $eq #gvhd--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced second quarter 2024 estimated ending cash, cash equivalents and short-term investments of approximately $33.3 million, representing an increase of approximately $1.0 million from the end of the first quarter of 2024. the increase is primarily the result of receiving a tax credit of.
EQ Ratings Summary
EQ Quant Ranking